JPMorgan Chase & Co. Trims Stock Position in Pediatrix Medical Group, Inc. (NYSE:MD)

JPMorgan Chase & Co. reduced its stake in Pediatrix Medical Group, Inc. (NYSE:MD - Free Report) by 5.9% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 942,312 shares of the company's stock after selling 59,509 shares during the period. JPMorgan Chase & Co. owned approximately 1.10% of Pediatrix Medical Group worth $10,921,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Rubric Capital Management LP grew its position in Pediatrix Medical Group by 797.0% in the 2nd quarter. Rubric Capital Management LP now owns 8,150,000 shares of the company's stock valued at $61,532,000 after acquiring an additional 7,241,400 shares in the last quarter. Dana Investment Advisors Inc. grew its position in Pediatrix Medical Group by 80.3% in the 2nd quarter. Dana Investment Advisors Inc. now owns 1,023,136 shares of the company's stock valued at $7,725,000 after acquiring an additional 455,785 shares in the last quarter. Weiss Asset Management LP grew its position in Pediatrix Medical Group by 50.5% in the 3rd quarter. Weiss Asset Management LP now owns 912,818 shares of the company's stock valued at $10,580,000 after acquiring an additional 306,143 shares in the last quarter. Cubist Systematic Strategies LLC grew its position in Pediatrix Medical Group by 639.4% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 290,336 shares of the company's stock valued at $2,192,000 after acquiring an additional 251,072 shares in the last quarter. Finally, RBF Capital LLC acquired a new position in Pediatrix Medical Group in the 3rd quarter valued at about $1,695,000. 97.71% of the stock is currently owned by hedge funds and other institutional investors.

Pediatrix Medical Group Stock Performance

NYSE MD traded up $0.86 on Monday, reaching $13.30. The stock had a trading volume of 695,458 shares, compared to its average volume of 466,465. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.42 and a current ratio of 1.42. Pediatrix Medical Group, Inc. has a 12-month low of $6.62 and a 12-month high of $16.41. The business's 50-day moving average price is $14.30 and its 200 day moving average price is $11.62. The stock has a market cap of $1.14 billion, a P/E ratio of -4.35, a price-to-earnings-growth ratio of 2.00 and a beta of 1.58.

Pediatrix Medical Group (NYSE:MD - Get Free Report) last released its quarterly earnings results on Friday, November 1st. The company reported $0.44 EPS for the quarter, topping the consensus estimate of $0.37 by $0.07. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. The business had revenue of $511.20 million during the quarter, compared to analysts' expectations of $498.87 million. During the same quarter in the prior year, the business earned $0.29 earnings per share. The company's quarterly revenue was up .9% compared to the same quarter last year. As a group, equities analysts expect that Pediatrix Medical Group, Inc. will post 1.26 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Mizuho lifted their target price on Pediatrix Medical Group from $13.00 to $15.00 and gave the company a "neutral" rating in a research report on Tuesday, November 19th. Jefferies Financial Group boosted their price objective on Pediatrix Medical Group from $14.00 to $18.00 and gave the stock a "buy" rating in a research report on Tuesday, November 5th. UBS Group boosted their price objective on Pediatrix Medical Group from $10.50 to $16.50 and gave the stock a "neutral" rating in a research report on Tuesday, November 5th. Deutsche Bank Aktiengesellschaft boosted their price objective on Pediatrix Medical Group from $9.00 to $15.00 and gave the stock a "hold" rating in a research report on Monday, November 4th. Finally, StockNews.com raised Pediatrix Medical Group from a "hold" rating to a "buy" rating in a report on Thursday. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $16.25.

Insider Transactions at Pediatrix Medical Group

In other Pediatrix Medical Group news, Director Mark S. Ordan sold 27,600 shares of the company's stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $15.35, for a total value of $423,660.00. Following the sale, the director now owns 138,683 shares of the company's stock, valued at approximately $2,128,784.05. This represents a 16.60 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Mary Ann E. Moore sold 8,108 shares of the stock in a transaction on Friday, November 8th. The shares were sold at an average price of $16.00, for a total value of $129,728.00. Following the sale, the executive vice president now directly owns 135,810 shares in the company, valued at approximately $2,172,960. The trade was a 5.63 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 2.00% of the company's stock.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.